Physician profile
John Fell
NPI 1629091640
$3,647.47
in general payments reported to CMS, 2019-2025
29 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $438 · 2021: $901 · 2022: $321 · 2023: $487 · 2024: $750 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,346.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $747.64 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $672.57 | 2019-2025 | Veozah |
| Abbvie INC. | $312.06 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $309.39 | 2020-2024 | Farxiga, Airsupra, Lokelma |
| Sanofi-Aventis U.S. LLC | $266.98 | 2019-2022 | |
| Amgen INC. | $175.49 | 2019-2020 | |
| Lilly USA, LLC | $150.45 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $133.67 | 2019-2024 | |
| Glaxosmithkline, LLC. | $132.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $115.53 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.00 | 2024 | Xifaxan |
| Allergan, INC. | $71.88 | 2020-2021 | |
| Abbott Laboratories | $68.23 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.46 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $54.68 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $50.35 | 2023 | |
| Exact Sciences Corporation | $30.74 | 2024 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $28.31 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $27.52 | 2024 | Fanapt |
| Horizon Therapeutics Plc | $26.95 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $18.14 | 2023 | |
| Janssen Pharmaceuticals, INC | $17.39 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.06 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $16.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.82 | 2024 | |
| Intra-Sana Laboratories | $15.81 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.35 | 2022 | |
| Antares Pharma, INC. | $14.73 | 2022 | |
| Radius Health, INC. | $11.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.